Picture loading failed.

Anti-DLL4;VEGFA therapeutic antibody (Pre-made Navicixizumab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Navicixizumab is an anti-DLL4/VEGF bispecific antibody that has demonstrated robust in vivo antitumor efficacy in a number of solid tumor xenografts. In the phase Ia trial of the monotherapy, 66 patients with various solid tumors were treated once every 3 weeks in 1 of 8 dose-escalation cohorts or an expansion cohort.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-369-1mg 1mg Inquiry
GMP-Bios-ab-369-10mg 10mg Inquiry
GMP-Bios-ab-369-100mg 100mg Inquiry
GMP-Bios-ab-369-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-DLL4;VEGFA therapeutic antibody (Pre-made Navicixizumab biosimilar,Bispecific mAb)
INN Name Navicixizumab
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2015
Year Recommended2016
CompaniesOncoMed Pharmaceuticals
Conditions Approvedna
Conditions ActiveFallopian tube cancer;Ovarian cancer;Peritoneal cancer
Conditions DiscontinuedColorectal cancer;Solid tumours
Development Techna